.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
McKinsey
Harvard Business School
Deloitte
McKesson
Cantor Fitzgerald
Colorcon
Baxter
Medtronic
Fuji

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,475,839

« Back to Dashboard

Which drugs does patent 8,475,839 protect, and when does it expire?


Patent 8,475,839 protects EXFORGE HCT and is included in one NDA. There have been two Paragraph IV challenges on Exforge HCT.

Protection for EXFORGE HCT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,475,839

Title:Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
Abstract: Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.
Inventor(s): Cao; Yu (Parsippany, NJ), Joshi; Yatindra (Princeton, NJ), Li; Ping (Basking Ridge, NJ), Pudipeddi; Madhusudhan (Mumbai, IN), Royce; Alan E (Saylorsburg, PA), Wagner; Robert F (Hillsborough, NJ), Zhu; Jiahao (Whippany, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:13/342,533
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
NovartisEXFORGE HCTamlodipine besylate; hydrochlorothiazide; valsartanTABLET;ORAL022314-001Apr 30, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
NovartisEXFORGE HCTamlodipine besylate; hydrochlorothiazide; valsartanTABLET;ORAL022314-002Apr 30, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
NovartisEXFORGE HCTamlodipine besylate; hydrochlorothiazide; valsartanTABLET;ORAL022314-003Apr 30, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
NovartisEXFORGE HCTamlodipine besylate; hydrochlorothiazide; valsartanTABLET;ORAL022314-004Apr 30, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
NovartisEXFORGE HCTamlodipine besylate; hydrochlorothiazide; valsartanTABLET;ORAL022314-005Apr 30, 2009ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
AstraZeneca
Harvard Business School
Teva
UBS
US Army
Julphar
Accenture
Baxter
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot